Research view
Switch to patient viewColorectal cancer: trials that stopped early
Trials on Colorectal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
254 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.
Terminated
Cryptosporidium Infection and Human Colorectal Cancer
Reason given in the registry “No other patients could be included within the time frame.”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Nov 2026.
- Ended
- Jun 2025
- Run by
- Lille Catholic University
- Registry record
- NCT04332705
Terminated
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Reason given in the registry “The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Nov 2026.
- Ended
- Oct 2026
- Phase
- Phase 1
- Run by
- Context Therapeutics Inc.
- Registry record
- NCT06756035
Withdrawn
ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer
Reason given in the registry “Funding issues”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Nov 2026.
- Run by
- Massachusetts General Hospital
- Registry record
- NCT05629442
Terminated
KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer
Reason given in the registry “The study was stopped early due to lack of efficacy.”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Nov 2026.
- Ended
- Sept 2026
- Phase
- Phase 2
- Run by
- Peking University Cancer Hospital & Institute
- Registry record
- NCT05985109
Suspended
Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
Reason given in the registry “PI Request”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Nov 2026.
- Phase
- Phase 2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT07011550
Suspended
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
Reason given in the registry “Protocol is with FDA review, waiting for funding to be released”
Quoted unchanged from ClinicalTrials.gov; record updated 28 Oct 2026.
- Phase
- Phase 2
- Run by
- Thomas Jefferson University
- Registry record
- NCT04111172
Terminated
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Reason given in the registry “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”
Quoted unchanged from ClinicalTrials.gov; record updated 26 Oct 2026.
- Ended
- Oct 2026
- Phase
- Phase 1/2
- Run by
- Merus B.V.
- Registry record
- NCT04868877
Terminated
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Reason given in the registry “Company's strategic decision”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Oct 2026.
- Ended
- Jun 2026
- Phase
- Phase 1
- Run by
- Astellas Pharma Inc
- Registry record
- NCT06364696
Terminated
The Impact of Laparotomy and Analgesia Methods on Diaphragm
Reason given in the registry “The study was terminated prematurely because the planned sample size could not be achieved due to insufficient participant recruitment.”
Quoted unchanged from ClinicalTrials.gov; record updated 22 Oct 2026.
- Ended
- Sept 2025
- Run by
- Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
- Registry record
- NCT06403540
Suspended
EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden
Reason given in the registry “Not enough patients”
Quoted unchanged from ClinicalTrials.gov; record updated 22 Oct 2026.
- Phase
- Phase 2
- Run by
- Oslo University Hospital
- Registry record
- NCT04840186
Terminated
HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.
Reason given in the registry “Following temporary halt of inclusion in September 2024, several measures were taken, as previuosly reported. As numbers included by September 2024 were sufficient to conclude for primary endpont, we have decided not to restart the trial.”
Quoted unchanged from ClinicalTrials.gov; record updated 22 Oct 2026.
- Ended
- Aug 2026
- Phase
- Phase 2
- Run by
- Oslo University Hospital
- Registry record
- NCT04898504
Suspended
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
Reason given in the registry “Pending amendment approval”
Quoted unchanged from ClinicalTrials.gov; record updated 21 Oct 2026.
- Phase
- Phase 1/2
- Run by
- Virginia Commonwealth University
- Registry record
- NCT03919292
Terminated
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Reason given in the registry “Business reasons and not based on any safety concerns.”
Quoted unchanged from ClinicalTrials.gov; record updated 21 Oct 2026.
- Ended
- Sept 2026
- Phase
- Phase 1/2
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT05358249
Terminated
EO4010 in Previously Treated Metastatic Colorectal Carcinoma
Reason given in the registry “Sponsor decision to stop recruitment in context of overall EO4010 development goals. Stop of recruitment was not related to any safety concern, with the safety profile of EO4010 being benign”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Oct 2026.
- Ended
- May 2025
- Phase
- Phase 1/2
- Run by
- Enterome
- Registry record
- NCT05589597
Terminated
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Reason given in the registry “Sponsor decision”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Oct 2026.
- Ended
- Feb 2026
- Phase
- Phase 1
- Run by
- Boehringer Ingelheim
- Registry record
- NCT06091930
Withdrawn
Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia
Reason given in the registry “organisational problems”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Oct 2026.
- Ended
- Apr 2024
- Phase
- Phase 4
- Run by
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Registry record
- NCT02032953
Withdrawn
Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer
Reason given in the registry “Study withdrawn before enrollment of any participant due to a corporate strategic decision. Not related to safety or efficacy concerns.”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Oct 2026.
- Phase
- Phase 3
- Run by
- Biotech Pharmaceutical Co., Ltd.
- Registry record
- NCT06343116
Suspended
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
Reason given in the registry “temporary suspended”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Oct 2026.
- Phase
- Phase 1
- Run by
- University of Alabama at Birmingham
- Registry record
- NCT06867822
Suspended
RCT of Mobile Apps & FitBit v. Usual Care
Reason given in the registry “Study is paused for interim analysis.”
Quoted unchanged from ClinicalTrials.gov; record updated 28 Sept 2026.
- Run by
- Weill Medical College of Cornell University
- Registry record
- NCT03623464
Terminated
Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases
Reason given in the registry “Low Accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Sept 2026.
- Ended
- May 2025
- Phase
- Phase 4
- Run by
- University of Colorado, Denver
- Registry record
- NCT04973007
Terminated
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Reason given in the registry “Sponsor decision based on limited anti-cancer activity of TAK-186.”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Sept 2026.
- Ended
- Jun 2025
- Phase
- Phase 1/2
- Run by
- Takeda
- Registry record
- NCT04844073
Suspended
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
Reason given in the registry “Administrative”
Quoted unchanged from ClinicalTrials.gov; record updated 21 Sept 2026.
- Run by
- ProgenaBiome
- Registry record
- NCT04031469
Suspended
CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer
Reason given in the registry “Strategy under discussion”
Quoted unchanged from ClinicalTrials.gov; record updated 18 Sept 2026.
- Phase
- Phase 2
- Run by
- Holy Stone Healthcare Co., Ltd
- Registry record
- NCT06039202
Suspended
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
Reason given in the registry “Currently no funding to continue study.”
Quoted unchanged from ClinicalTrials.gov; record updated 18 Sept 2026.
- Run by
- Persephone Biosciences
- Registry record
- NCT04638751
Withdrawn
Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer
Reason given in the registry “0 participants”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Sept 2026.
- Ended
- Sept 2026
- Phase
- Phase 2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT07720115
Terminated
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
Reason given in the registry “This was a strategic business decision. There were no safety concerns contributing to this decision.”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Sept 2026.
- Ended
- Jul 2025
- Phase
- Phase 1
- Run by
- Incyte Corporation
- Registry record
- NCT06039384
Terminated
Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
Reason given in the registry “Accrual was terminated due to safety concerns”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Sept 2026.
- Ended
- Oct 2024
- Phase
- Phase 2
- Run by
- University of Colorado, Denver
- Registry record
- NCT05167409
Terminated
Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer Survivors
Reason given in the registry “Terminated due to low accrual.”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Sept 2026.
- Ended
- Jun 2026
- Run by
- Fred Hutchinson Cancer Center
- Registry record
- NCT05930496
Withdrawn
IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations
Reason given in the registry “Study was stopped Sponsor discretion. No patients were dosed.”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Sept 2026.
- Phase
- Phase 1
- Run by
- Shanghai Pudong Hospital
- Registry record
- NCT06487377
Withdrawn
xDRIVE in Metastatic Colorectal Cancer
Reason given in the registry “Unable to finalize study agreements”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Sept 2026.
- Run by
- First Ascent Biomedical Inc.
- Registry record
- NCT06929338
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.